Isabella Visuri
Isabella Visuri Position: Doctoral Student School/office: School of Medical SciencesEmail: aXNhYmVsbGEudmlzdXJpO29ydS5zZQ==
Phone: +46 19 302181
Room: X2102
Publications
Articles in journals |
Conference papers |
Doctoral theses, comprehensive summaries |
Manuscripts |
Articles in journals
- Thunberg, J. , Grännö, O. , Bergemalm, D. , Eriksson, C. , Visuri, I. , Eberhardson, M. & Halfvarson, J. (2024). Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels. Scandinavian Journal of Gastroenterology, 59 (2), 150-155. [BibTeX]
- Visuri, I. , Eriksson, C. , Karlqvist, S. , Lykiardopoulos, B. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2023). Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study. Therapeutic Advances in Gastroenterology, 16. [BibTeX]
- Holmgren, J. , Fröborg, A. , Visuri, I. , Halfvarson, J. , Hjortswang, H. , Karling, P. , Myrelid, P. , Olén, O. & et al. (2023). The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Inflammatory Bowel Diseases, 19 (3), 339-348. [BibTeX]
- Eriksson, C. , Visuri, I. , Vigren, L. , Nilsson, L. , Kärnell, A. , Hjortswang, H. , Bergemalm, D. , Almer, S. & et al. (2021). Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scandinavian Journal of Gastroenterology, 56 (11), 1304-1311. [BibTeX]
- Visuri, I. , Eriksson, C. , Olén, O. , Cao, Y. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. & et al. (2021). Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Alimentary Pharmacology and Therapeutics, 54 (7), 931-943. [BibTeX]
- Shrestha, S. , Olén, O. , Eriksson, C. , Everhov, Å. H. , Myrelid, P. , Visuri, I. , Ludvigsson, J. F. , Schoultz, I. & et al. (2020). The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register. Scandinavian Journal of Gastroenterology, 55 (4), 430-435. [BibTeX]
Conference papers
- Visuri, I. , Eriksson, C. , Mårdberg, E. , Grip, O. , Gustavsson, A. , Hjortswang, H. , Karling, P. , Montgomery, S. & et al. (2019). Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG). In: Journal of Crohn's & Colitis. Oxford University Press. [BibTeX]
- Eriksson, C. , Bergemalm, D. , Vigren, L. , Nilsson, L. , Visuri, I. , Hjortswang, H. , Udumyan, R. , Almer, S. & et al. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. In: Journal of Crohn's & Colitis. Paper presented at 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. (pp. S409-S410). Oxford University Press. [BibTeX]
Doctoral theses, comprehensive summaries
- Visuri, I. (2024). Biological treatment in inflammatory bowel disease: clinical and therapeutic aspects. (Doctoral dissertation). (Comprehensive summary) Örebro: Örebro University. [BibTeX]
Manuscripts
- Visuri, I. , Dannenberg, K. , Salomon, B. , Ling Lundström, M. , Bergemalm, D. , Eriksson, C. , Lindqvist, C. M. , Keita, Å. V. & et al. Correlations of clinical characteristics and serum proteins with drug levels : A multicentre cohort study of patients with inflammatory bowel disease starting biologics. [BibTeX]